Sucampo Announces Presentation of Results on AMITIZA(R) (lubiprostone) in Opioid-Induced Constipation at Two Upcoming Scientific Conferences
11 oct. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of three posters evaluating AMITIZA® (lubiprostone) in...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at BioCentury(R) NewsMakers in the Biotech Industry 2013 Conference
20 sept. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...
Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology
12 sept. 2013 19h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Sucampo AG ("SAG"), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), announced today that it will present four...